On Thursday, Arch Coal Inc (NYSE:ACI)’s shares declined -38.50% to $1.31.
Arch Coal, Inc. (ACI) declared the extension of its (i) pending private offer to exchange (the “2020 Exchange Offer”) new 6.25% Trust Certificates due 2021 (the “Trust Certificates”) and a cash payment for any and all of its outstanding 7.25% Senior Notes due 2020 (the “2020 Notes”) and (ii) pending concurrent private offer to exchange (the “Concurrent Exchange Offer” and, together with the 2020 Exchange Offer, the “Exchange Offers”) Trust Certificates, 8.00% Senior Secured Notes due 2022 (the “New 2022 Secured Notes”) and 12.00% Senior Secured Second Lien Notes due 2023 (the “New 2023 Secured Notes”) for its outstanding 7.000% Senior Notes due 2019 (“Old 7.000% 2019 Notes”), 9.875% Senior Notes due 2019 (“Old 9.875% 2019 Notes”) and 7.250% Senior Notes due 2021 (“Old 7.250% 2021 Notes” and, together with the Old 7.000% 2019 Notes and the Old 9.875% 2019 Notes, the “Old Notes”).
Arch Coal, Inc. produces and sells thermal and metallurgical coal from surface and underground mines located in the United States. As of December 31, 2014, it operated or contracted out the operation of 16 mines; and owned or controlled about 5.1 billion tons of proven and probable recoverable reserves.
Delaware Invstmt Mnst Mnpl Inm Fd II Inc (NYSEMKT:VMM)’s shares gained dropped XXX% to $13.23.
Monster Beverage Corporation (MNST) stated financial results for the second quarter and six months ended June 30, 2015.
As a result of the transaction, the Company incurred obligations related to distributor terminations in the amount of $12.2 million and $218.2 million during the three and six months ended June 30, 2015, respectively. Such termination costs have been expensed in full and are comprised of in operating expenses for the corresponding periods. In addition, the Company recognized revenue of $39.8 million related to the acceleration of deferred revenue associated with the terminated distributors during the first half of 2015 and incurred transaction expenses of $11.5 million in the second quarter of 2015 and $15.1 million in the first half of 2015.
Monster Beverage Corporation, through its auxiliaries, develops, markets, sells, and distributes alternative beverage category beverages in the United States and internationally. It operates in two segments, Direct Store Delivery and Warehouse. The Direct Store Delivery segment offers carbonated energy drinks, non-carbonated dairy based coffee plus energy drinks, non-carbonated energy shakes containing proteins, carbonated energy drinks containing nitrous oxide, non-carbonated energy drinks with electrolytes, and ready-to-drink iced teas.
At the end of Thursday’s trade, Celldex Therapeutics, Inc. (NASDAQ:CLDX)‘s shares dipped -0.66 to $16.50.
Celldex Therapeutics, Inc. (CLDX) stated business and financial highlights for the second quarter ended June 30, 2015.
Program Updates:
RINTEGA(R) (“rindopepimut”; “rindo”; CDX-110), an EGFRvIII(v3)-specific therapeutic vaccine for glioblastoma (GBM)
- In June, the independent Data Safety and Monitoring Board (DSMB) recommended continuation of the Phase 3 ACT IV study of RINTEGA(R) (rindopepimut) in patients with newly diagnosed glioblastoma as a result of a prespecified interim analysis assessing safety, futility and efficacy at 50% of events (deaths). The ACT IV study is a randomized, double-blind, placebo controlled study of RINTEGA plus GM-CSF added to standard of care temozolomide in patients with newly diagnosed, surgically resected, EGFRvIII-positive glioblastoma. 745 patients were enrolled into ACT IV to reach the required 374 patients with minimal residual disease (assessed by central review) needed for analysis of the primary overall survival endpoint. All patients, counting those with disease that exceed this threshold, will be comprised of in a secondary analysis of overall survival in addition to analyses of progression-free survival, safety and tolerability, and quality of life. The second interim analysis is predictable to occur in late 2015/early 2016.
Celldex Therapeutics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes novel therapeutics for human health care in the United States. The company’s lead drug candidates comprise rindopepimut (CDX-110), a targeted immunotherapeutic in a pivotal Phase III study for the treatment of front-line glioblastoma, in addition to in Phase II study for the treatment of recurrent glioblastoma; and Glembatumumab vedotin (CDX-011), a targeted antibody-drug conjugate in a randomized Phase IIb study for the treatment of triple negative breast cancer, in addition to in Phase II study for the treatment of metastatic melanoma.
ABIOMED, Inc. (NASDAQ:ABMD), ended its Thursday’s trading session with 5.07% gain, and closed at $105.75.
Abiomed, Inc. (ABMD), a leading provider of breakthrough heart support technologies, stated first quarter fiscal 2016 revenue of $73.4 million, an enhance of 50% contrast to revenue of $48.8 million for the same period of fiscal 2015. First quarter fiscal 2016 GAAP net income was $8.9 million or $0.20 per diluted share, contrast to GAAP net loss of $1.7 million or a loss of $0.04 per diluted share for the preceding year period.
Financial and operating highlights during the first quarter of fiscal 2016 comprise:
- Fiscal first quarter worldwide Impella® revenue totaled $68.8 million, an enhance of 53% contrast to revenue of $45.0 million during the same period of the preceding fiscal year. U.S. Impella revenue grew 60% to $63.7 million from $39.9 million in the preceding fiscal year with U.S. Impella patient usage up 62%.
- An additional 15 hospitals made initial purchases of Impella during the quarter, contrast to 24 new hospital sites in the preceding year period, bringing the installed customer base to 973 sites. As part of Abiomed’s continued Impella CP® launch, 54 new hospitals purchased Impella CP, bringing the total number of Impella CP U.S. sites to 694.
ABIOMED, Inc. researches, develops, and sells medical devices in circulatory support and continuum of care in heart recovery to acute heart failure patients. The company offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; Impella CP that provides partial circulatory support using an extracorporeal bypass control unit; Impella 5.0 catheter and Impella LD, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; and Impella RP, a percutaneous catheter-based axial flow pump.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
